Silexion Therapeutics has received approval from the Israeli Ministry of Health to begin a Phase 2/3 clinical trial of SIL204, a next-generation RNAi therapy targeting KRAS mutations in locally advanced pancreatic cancer. This milestone follows positive preclinical results and successful toxicology studies, positioning SIL204 as a promising treatment for a cancer type with high unmet medical need. The company plans to start the trial in Q2 2026 and aims to expand regulatory filings in Europe by early 2027, advancing its clinical-stage development focused on KRAS-driven cancers.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Kenmare Resources reported weaker-than-expected production in the first half of 2026 due to commissioning delays at its Wet Concentrator Plant A, with ilmenite output down 40% year on year in Q2. Despite this, shipments increased by 53% as the compan...
Ramsdens Holdings PLC shares rose 13.6% to 670p following an improved takeover offer from US pawnbroking group FirstCash. FirstCash increased its cash bid to 675p per share from 600p, raising the total offer value to up to £232 million, including div...
Alphamin Resources delivers strong free cash flow from its high-grade Bisie tin mine, maintaining consistent output of 20,000 tonnes per annum. Despite operational risks in the Democratic Republic of Congo, the company trades at a significant valuati...
Rotork PLC agreed to a £4.1 billion takeover by Switzerland's ABB, sending its shares up 67% and boosting the UK industrial engineering sector. The offer includes a 73% premium and an interim dividend, reflecting strong overseas interest in UK manufa...
